Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study

What Was Tested

This randomized controlled trial paper looks at Buserelin in the context of endometriosis.

To evaluate the changes of pain symptoms induced by buserelin acetate, a gonadotropin-releasing hormone agonist, in a group of patients with endometriosis.

Who Took Part

PubMed tags the participants as women only.

Thirty-five infertile patients with one or more of the following symptoms (dysmenorrhea, pelvic pain, deep dyspareunia, and endometriosis stage I or II) were allocated randomly to treatment with buserelin acetate 1,200 micrograms/d IN for 6 months (n = 19) or expectant management (n = 16).

Pain symptoms were recorded by the women themselves using a questionnaire that included two scales for pain evaluation: one analogue and one multidimensional.

How the Study Was Run

The design is described as randomized.

Because people in this Buserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A time span of 6 months appears in the methods.

What Was Measured

Topics PubMed links to this paper include Buserelin, Dysmenorrhea, Endometriosis, Pain and Pelvis.

What This Means in Plain Language

The paper is a randomized study of Buserelin in people with endometriosis over 6 months.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1993 (Fertility and sterility), a journal based in United States.

More context: the Buserelin compound page, Endometriosis research.